Last updated: February 23, 2026
What is the Drug?
NDC 82667-0200 corresponds to Ravulizumab-cwvz (brand name: Tavneos), approved by the FDA in 2022. It is indicated for the treatment of ANCA-associated vasculitis (AAV), an autoimmune disorder with serious systemic implications. As a complement inhibitor, Tavneos offers a targeted therapy option that addresses a specific pathophysiological pathway.
Market Size and Key Drivers
Patient Population
- Estimated prevalence of AAV in the US: approximately 3-5 cases per 100,000 annually.
- US eligible patient base: roughly 10,000 to 15,000 individuals.
- Diagnosed and treated population: around 50% of patients diagnosed receive targeted therapy.
Competitive Landscape
- Existing Alternatives: Rituximab (Rituxan) and cyclophosphamide are standard treatments.
- Differentiation Factors: Tavneos provides a more targeted, potentially less toxic option, which could improve remission rates and reduce adverse effects.
Market Penetration Factors
- Prescriber acceptance: Limited initial adoption due to familiarity with existing therapies.
- Regulatory pathway: Approved via FDA's accelerated pathway; this may influence early market uptake.
- Reimbursement status: Coverage policies are emerging; initial reimbursement may be limited.
Revenue Estimates
- First-year revenue projection: $50-150 million, considering initial uptake and limited patient access.
- Five-year outlook: $300-500 million, assuming gradual adoption and increased awareness.
- Growth driven by expanded indications, value-based pricing, and patient access programs.
Pricing Strategy
- Current list price: approximately $530,000 to $580,000 per year per patient (comparable to complement inhibitors like eculizumab).
- Pricing assumptions aligned with premium biologics targeting rare diseases.
Price Projections and Trends
| Year |
Price Range per Patient |
Estimated Market Share |
Revenue Estimate |
| 2023 |
$530,000 – $580,000 |
5% |
$31 million – $58 million |
| 2024 |
$530,000 – $580,000 |
10% |
$60 million – $116 million |
| 2025 |
$530,000 – $580,000 |
15% |
$125 million – $168 million |
| 2026 |
$530,000 – $580,000 |
20% |
$210 million – $232 million |
Pricing stability depends on biosimilar development, negotiations with payers, and competitive pressures.
Market Challenges and Risks
- Pricing pressure: Payers may negotiate for discounts, especially if biosimilars or generics enter the market.
- Limited patient population: Small target group caps revenue potential.
- Reimbursement hurdles: Delays in coverage or prior authorization requirements can slow adoption.
- Clinical adoption: Prescriber hesitation to switch from established therapies.
Policy and Regulatory Impact
- The drug benefits from regulatory exclusivity due to its novel mechanism.
- Price settings are influenced by reimbursement policies for rare disease drugs.
- Health systems may implement value-based agreements to manage costs.
Key Takeaways
- The drug targets a niche autoimmune condition with an estimated 10,000–15,000 patients in the US.
- Initial pricing is high, with expected annual costs around $530,000–$580,000.
- Revenue projections range from $50 million initially to over $500 million within five years, contingent on market penetration and reimbursement.
- Competition from existing therapies and biosimilars presents a primary risk.
- Market growth depends on prescriber acceptance, payer negotiations, and broader indication expansion.
FAQs
1. How does Tavneos compare to existing treatments for AAV?
It offers a targeted mechanism with potential for fewer side effects and improved remission rates but faces competition from established therapies like Rituximab.
2. What factors influence future pricing of NDC 82667-0200?
Patents, biosimilar development, payer policies, and clinical value assessments impact pricing.
3. What is the likelihood of biosimilar competition?
High in the five- to eight-year horizon, once patent exclusivity periods expire, which could force price reductions.
4. How do reimbursement policies affect revenue projections?
Stringent reimbursement criteria can delay adoption and reduce gross revenue, especially if cost-effectiveness is challenged.
5. Are there expansion opportunities for this drug?
Yes, potential expansion into other complement-mediated disorders or broader autoimmune indications could increase market size.
References
[1] Food and Drug Administration (FDA). (2022). Tavneos approval announcement.
[2] Market data for rare autoimmune diseases. (2023). Pharma Intelligence.
[3] Pricing information for complement inhibitors. (2023). GoodRx.
[4] Biosimilar development timelines. (2022). FDA.gov.
